Clinical Trial Update: Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating chidamide in combination with an EGFR tyrosine kinase inhibitor for advanced EGFR-TKI-resistant non-small cell lung cancer; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chidamide (chidamide)
• EGFR-TKI (EGFR tyrosine kinase inhibitor)

Snippet

Sponsor: Yuankai Shi | Conditions: Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN